Senti Biosciences(US:SNTI) Globenewswireยท2025-08-07 12:05Core Insights - Senti Biosciences, Inc. is advancing its clinical development of SENTI-202, having completed the dose finding phase and confirmed the recommended Phase 2 dose (RP2D) for treating relapsed/refractory AML [2][7] - The company received Orphan Drug Designation from the U.S. FDA for SENTI-202, enhancing its potential market position [7] - Senti Bio aims to grow its pipeline and expects to release additional efficacy and durability data from its ongoing Phase 1 study by the end of the year [2] Recent Pipeline and Corporate Updates - The company has completed the dose finding phase for SENTI-202 and is currently in the dose expansion phase [2][7] - Senti Bio received a $1.0 million tranche from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of SENTI-202 [7] - New appointments to the leadership team include Bryan Baum to the Board of Directors and Dr. James B. Trager to the Scientific Advisory Board [7] Financial Results for Q2 2025 - As of June 30, 2025, Senti Bio reported cash and cash equivalents of approximately $21.6 million, down from $48.3 million as of December 31, 2024 [7][13] - Research and development expenses increased to $10.0 million for Q2 2025, compared to $9.2 million in Q2 2024, primarily due to higher external services and supplies costs [7][15] - General and administrative expenses rose to $6.8 million in Q2 2025 from $4.2 million in Q2 2024, mainly due to increased personnel-related expenses [7][15] - The net loss for Q2 2025 was $14.7 million, or $0.56 per share, compared to a net loss of $11.2 million in Q2 2024 [7][15][16]